Soft Loans and Grants

AbilityPharma shareholders include the venture capital firm Inveready, private investors and the founders of the company.

This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.
The company has obtained grants and soft loans from high level public institutions:
  • NEBT grant from ACCIÓ, Government of Catalonia.
  • Technological Innovation Nuclei grant from ACCIÓ, Government of Catalonia.
  • PID soft loan from CDTI, Government of Spain.
  • Innoglobal from CDTI, Government of Spain.
  • Innocash from Fundación Genoma España, Government of Spain.
  • ENISA (National Innovation Company), Ministry of Industry, Energy and Tourism, Government of Spain.
  • Investment Readiness program from ACC1Ó, Government of Catalonia.
  • Torres-Quevedo grants from MINECO, Government of Spain.
  • International Talent grant from Biocat (Bioregion Catalonia), Government of Catalonia.
  • Inncorpora soft loan from the Ministry of Economy and Competitivity, Government of Spain.
  • Innpacto soft loan from the Ministry of Economy and Competitivity, Government of Spain.
  • Retos soft loan from the Ministry of Economy and Competitivity, Government of Spain.

Ability Pharmaceuticals participates in the projects"Development of new cancer therapies with high efficiency and specificity and low oral toxicity" and "Development of new financed by the call Retos-Colaboración del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, with the dossier numbers: RTC-2014-1532-1 i RTC -2014-2589-1 respectively.

Ability Pharmaceuticals participates in the project  "New therapeutic approaches based on derivatives of essential fatty acids targeted to unmet needs in oncological and neurological diseases" funded by the INNPACTO call of the Spanish Research Program (MINECO) with dossier number  IPT- 2012-0614-010000.

The project called "Clinical Investigation of ABTL0812 in combination with chemotherapy in non-small cell lung cancer and identification of associated biomarkers", has been subsidized by the CDTI and supported by the Ministry of Economy, Industry and Competitiveness, under the file number INNO-20171061 .

Ability Pharmaceuticals has received grants for recruitment : Torres Quevedo (PTQ-11-04900, PTQ-12-05453), Inncorpora (INC-TU-2012-2617) and Emplea (EMP-2015-4578 -2015 and EMP-2015-4569).

The Ministry of Science, Innovation and Universities, within the State Plan for Scientific and Technical Research and Innovation 2013-2016, granted assistance to the project "NEW STRATEGIES TO INCREASE EFFECTIVENESS OF TREATMENTS WITH ABTL0812" led by Ability Pharmaceuticals SL with file number RTC -2017-6261-1.

This project has been funded by the Ministry of Science, Innovation and Universities within the RETOS-COLLABORATION Subprogram, Call 2017.

The project is co-financed by the European Union with the aim of promoting technological development, innovation and quality research.



Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info

Press Release


Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police